FDA Investigates Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
The US Food and Drug Administration (FDA) has issued a safety communication regarding postmarketing reports of malignancies in patients treated with the gene therapy Zolgensma for spinal muscular atrophy. The reports include confirmed cases of product-related insertional oncogenesis involving the GLI1 oncogene, with molecular analyses demonstrating AAV vector DNA integration into the host genome.
The investigation applies to both Zolgensma and Itvisma because they contain the same vector and construct. Postmarketing tumor formations have been reported in the central and peripheral nervous systems, spinal or paraspinal regions, and the kidney, though the overall benefits of the therapies continue to outweigh their potential risks for approved uses.
The FDA is currently evaluating the adequacy of current prescribing information and long-term follow-up studies to mitigate this serious risk. Healthcare providers are advised to monitor patients receiving these therapies for tumor formation and to report any suspected adverse reactions.
Key points
- FDA received postmarketing reports of malignancies in patients treated with Zolgensma.
- Molecular analysis confirmed product-related insertional oncogenesis involving the GLI1 oncogene.
- The risk applies to both Zolgensma and Itvisma as they share the same vector and construct.
- Healthcare providers should monitor treated patients for tumor formation and report adverse reactions.
What it means for you
Clinicians and pharmacists managing pediatric or adult patients receiving gene therapies should remain vigilant for signs of tumor formation and review any new safety communications. Because regulatory status and local product availability can vary, clinicians in Pakistan should check with the Drug Regulatory Authority of Pakistan (DRAP) for any specific local guidance.
MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.